Carbonic anhydrases II and XII are up-regulated in osteoclast-like cells in advanced human atherosclerotic plaques—Tampere Vascular Study

References

• Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Asotra K, . Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J. 2002;16:577–82.
   PubMed Web of Science ®Google Scholar
• Jeziorska M, McCollum C, Wooley DE. Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries. Virchows Arch. 1998;433:559–65.
   PubMed Web of Science ®Google Scholar
• Schmid K, McSharry WO, Pameijer CH, Binette JP. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis. 1980;37: 199–210.
   PubMed Web of Science ®Google Scholar
• Detrano RC, Doherty TM, Davies MJ, Stary HC. Predicting coronary events with coronary calcium: pathophysiologic and clinical problems. Curr Probl Cardiol. 2000;25: 374–402.
   PubMed Web of Science ®Google Scholar
• Stary HC. Natural history of calcium deposits in atherosclerosis progression and regression. Z Kardiol. 2000;89 Suppl 2:28–35.
   PubMedGoogle Scholar
• Schinke T, McKee MD, Karsenty G. Extracellular matrix calcification: where is the action? Nat Genet. 1999;21:150–1.
   PubMed Web of Science ®Google Scholar
• Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423:349–55.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.
   PubMed Web of Science ®Google Scholar
• Riihonen R, Supuran CT, Parkkila S, Pastorekova S, Vaananen HK, Laitala-Leinonen T. Membrane-bound carbonic anhydrases in osteoclasts. Bone. 2007;40:1021–31.
   PubMed Web of Science ®Google Scholar
• Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, . Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998–2003.
   PubMed Web of Science ®Google Scholar
• Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, . Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386: 78–81.
   PubMed Web of Science ®Google Scholar
• Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91: 1800–9.
   PubMed Web of Science ®Google Scholar
• Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, Khalapyan T, . Bone formation in carotid plaques: a clinicopathological study. Stroke. 2002;33:1214–9.
   PubMed Web of Science ®Google Scholar
• Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050–5.
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–8.
   PubMed Web of Science ®Google Scholar
• Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002;143:1108–18.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 2004; 19:199–229.
   PubMed Web of Science ®Google Scholar
• Hilvo M, Tolvanen M, Clark A, Shen B, Shah GN, Waheed A, . Characterization of CA XV, a new GPI-anchored form of carbonic anhydrase. Biochem J. 2005;392(Pt 1):83–92.
   PubMedGoogle Scholar
• Halmi P, Lehtonen J, Waheed A, Sly WS, Parkkila S. Expression of hypoxia-inducible, membrane-bound carbonic anhydrase isozyme XII in mouse tissues. Anat Rec A Discov Mol Cell Evol Biol. 2004;277:171–7.
   PubMedGoogle Scholar
• Gamble W. Atherosclerosis: the carbonic anhydrase, carbon dioxide, calcium concerted theory. J Theor Biol. 2006;239:16–21.
   PubMed Web of Science ®Google Scholar
• Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, Jarvinen O, . ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries—Tampere vascular study. Ann Med. 2009;41:279–90.
   PubMed Web of Science ®Google Scholar
• Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, . A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–74.
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, . A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE. 2006;1:e97.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
   PubMed Web of Science ®Google Scholar
• Parkkila AK, Parkkila S, Juvonen T, Rajaniemi H. Carbonic anhydrase isoenzymes II and I are present in the zona glomerulosa cells of the human adrenal gland. Histochemistry. 1993;99:37–41.
   PubMedGoogle Scholar
• Karhumaa P, Parkkila S, Tureci O, Waheed A, Grubb JH, Shah G, . Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol Hum Reprod. 2000;6:68–74.
   PubMed Web of Science ®Google Scholar
• Toyosawa S, Ogawa Y, Chang CK, Hong SS, Yagi T, Kuwahara H, . Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours. Virchows Arch A Pathol Anat Histopathol. 1991;418:255–61.
   PubMedGoogle Scholar
• Hayman AR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 2008;41:218–23.
   PubMed Web of Science ®Google Scholar
• Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52:499–509.
   PubMed Web of Science ®Google Scholar
• Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741–8.
   PubMed Web of Science ®Google Scholar
• Rettenmier CW, Sacca R, Furman WL, Roussel MF, Holt JT, Nienhuis AW, . Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. J Clin Invest. 1986;77:1740–6.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell. 1985;41:665–76.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Rettenmier CW, Roussel MF. Macrophage colony-stimulating factor, CSF-1, and its proto-oncogene-encoded receptor. Cold Spring Harb Symp Quant Biol. 1988;53 Pt 1:521–30.
   PubMedGoogle Scholar
• Segovia-Silvestre T, Neutzsky-Wulff AV, Sorensen MG, Christiansen C, Bollerslev J, Karsdal MA, . Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet. 2009;124:561–77.
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, . Characterization of osteoclast precursors in human blood. Br J Haematol. 2000;111:501–12.
   PubMed Web of Science ®Google Scholar
• Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-Rochas M, Levi G, . Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol. 2008;173:773–80.
   PubMed Web of Science ®Google Scholar
• Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, . Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161:2035–46.
   PubMed Web of Science ®Google Scholar
• Athanasou NA, Quinn JM. Human tumour-associated macrophages are capable of bone resorption. Br J Cancer. 1992;65:523–6.
   PubMed Web of Science ®Google Scholar
• Athanasou NA, Quinn J. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol. 1990;43:997–1003.
   PubMed Web of Science ®Google Scholar
• Athanasou NA, Alvarez JI, Ross FP, Quinn JM, Teitelbaum SL. Species differences in the immunophenotype of osteoclasts and mononuclear phagocytes. Calcif Tissue Int. 1992;50:427–32.
   PubMed Web of Science ®Google Scholar
• da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogendoorn PC, Egeler RM. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med. 2005;201:687–93.
   PubMed Web of Science ®Google Scholar
• Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998;101:1468–78.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest. 1994;94: 1597–604.
   PubMed Web of Science ®Google Scholar
• Korhonen K, Parkkila AK, Helen P, Valimaki R, Pastorekova S, Pastorek J, . Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features. J Neurosurg. 2009;111: 472–7.
   PubMed Web of Science ®Google Scholar
• Haapasalo J, Nordfors K, Jarvela S, Bragge H, Rantala I, Parkkila AK, . Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol. 2007;9:308–13.
   PubMed Web of Science ®Google Scholar
• Leppilampi M, Koistinen P, Savolainen ER, Hannuksela J, Parkkila AK, Niemela O, . The expression of carbonic anhydrase II in hematological malignancies. Clin Cancer Res. 2002;8:2240–5.
   PubMed Web of Science ®Google Scholar
• Haapasalo J, Hilvo M, Nordfors K, Haapasalo H, Parkkila S, Hyrskyluoto A, . Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol. 2008;10:131–8.
   PubMed Web of Science ®Google Scholar
• Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivela J, Pastorekova S, . Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology. 2006;49:594–602.
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Vollmar E, Siemer S, Gottert E, Seitz G, . Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci U S A. 1998;95:7608–13.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–8.
   PubMed Web of Science ®Google Scholar
• Lehenkari P, Hentunen TA, Laitala-Leinonen T, Tuukkanen J, Vaananen HK. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+. Exp Cell Res. 1998;242:128–37.
   PubMed Web of Science ®Google Scholar
• Laitala T, Vaananen HK. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase. J Clin Invest. 1994;93:2311–8.
   PubMed Web of Science ®Google Scholar
• Sundquist KT, Vaananen HK, Marks SC Jr. Carbonic anhydrase II and H+-ATPase in osteoclasts of four osteopetrotic mutations in the rat. Histochem Cell Biol. 1999;111:55–60.
   PubMed Web of Science ®Google Scholar
• Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998;102:576–83.
   PubMed Web of Science ®Google Scholar
• Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95:1046–57.
   PubMed Web of Science ®Google Scholar
• Guzel O, Innocenti A, Scozzafava A, Salman A, Parkkila S, Hilvo M, . Carbonic anhydrase inhibitors: synthesis and inhibition studies against mammalian isoforms I-XV with a series of 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H- indole-5-sulfonamides. Bioorg Med Chem. 2008;16: 9113–20.
   PubMed Web of Science ®Google Scholar
• Innocenti A, Scozzafava A, Parkkila S, Puccetti L, De Simone G, Supuran CT. Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates. Bioorg Med Chem Lett. 2008;18:2267–71.
   PubMed Web of Science ®Google Scholar
• Dogne JM, Thiry A, Supuran CT. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs. Curr Pharm Des. 2008;14:679–84.
   PubMed Web of Science ®Google Scholar
• Knudsen JF, Carlsson U, Hammarstrom P, Sokol GH, Cantilena LR. The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. Inflammation. 2004;28:285–90.
   PubMed Web of Science ®Google Scholar
• Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, . Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550–7.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ‘selective’ inhibitor celecoxib. Bioorg Med Chem Lett. 2006;16:437–42.
   PubMed Web of Science ®Google Scholar
• Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, . Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. J Bone Miner Res. 2006;21:219–27.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–9.
   PubMed Web of Science ®Google Scholar